PMID- 32045142
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 25
IP  - 11
DP  - 2019 Nov 15
TI  - Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.
LID - 13030/qt3nw0p7hn [pii]
AB  - Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common 
      subtype of drug-induced systemic lupus erythematosus and has been associated with 
      more than 100 drugs. It presents weeks to months after initiation of the culprit 
      medication. The eruption is typically in a photodistribution and it is marked by 
      positive serology to anti-Ro (SSA) antibody. Systemic 5-fluorouracil (5-FU) is a 
      less-common culprit of drug-induced SCLE and its occurrence is likely dependent 
      on exposure to ultraviolet light. Herein, we present a review of drug-induced 
      lupus induced by the pyrimidine analog, 5-FU, and its prodrugs, capecitabine and 
      uracil-tegafur. The search was carried out using the following terms: (PubMed: 
      keywords included drug-induced lupus, 5-fluorouracil, subacute cutaneous lupus 
      erythematosus, capecitabine, uracil-tegafur, discoid lupus, systemic lupus 
      erythematosus).
FAU - Shakhbazova, Anastasia
AU  - Shakhbazova A
FAU - Marsch, Amanda F
AU  - Marsch AF
AD  - Department of Dermatology, University of California San Diego, La Jolla, CA. 
      amarsch@health.ucsd.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191115
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 1548R74NSZ (Tegafur)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Age Distribution
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*adverse effects
MH  - Capecitabine/adverse effects
MH  - Female
MH  - Fluorouracil/*adverse effects
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced
MH  - Lupus Erythematosus, Systemic/chemically induced
MH  - Male
MH  - Middle Aged
MH  - Sex Distribution
MH  - Tegafur/adverse effects
EDAT- 2020/02/12 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/02/12 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2020/02/12 06:00 [entrez]
PHST- 2020/02/12 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 13030/qt3nw0p7hn [pii]
PST - epublish
SO  - Dermatol Online J. 2019 Nov 15;25(11):13030/qt3nw0p7hn.